EML4 and non-small cell lung carcinoma: With high selectivity and safety, XMU‐MP‐5 can be used as a good start point for the new‐generation ALK inhibitors to overcome acquired resistance during the clinical treatment of EML4‐ALK‐positive NSCLC.